Skip to main content

Peer Review reports

From: ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

Original Submission
13 Aug 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
11 Oct 2022 Reviewed Reviewer Report
12 Oct 2022 Reviewed Reviewer Report
18 Oct 2022 Reviewed Reviewer Report
31 Oct 2022 Reviewed Reviewer Report
21 Nov 2022 Author responded Author comments - Yanguo Liu
Resubmission - Version 3
21 Nov 2022 Submitted Manuscript version 3
22 Nov 2022 Author responded Author comments - Yanguo Liu
Resubmission - Version 4
22 Nov 2022 Submitted Manuscript version 4
22 Nov 2022 Author responded Author comments - Yanguo Liu
Resubmission - Version 5
22 Nov 2022 Submitted Manuscript version 5
30 Nov 2022 Reviewed Reviewer Report
2 Dec 2022 Reviewed Reviewer Report
6 Dec 2022 Reviewed Reviewer Report
Resubmission - Version 6
Submitted Manuscript version 6
Publishing
7 Dec 2022 Editorially accepted
20 Dec 2022 Article published 10.1186/s12890-022-02279-2

You can find further information about peer review here.

Back to article page